ANDA 200300, held by Hikma Farmaceutica. Clonidine Hydrochloride.
As of Nov 16, 2026, ANDA 200300 (Clonidine Hydrochloride), held by Hikma Farmaceutica, was first approved by FDA on Jan 26, 2011, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Clonidine Hydrochloride Injection, USP is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY: Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2011 | Original application | Approved | None posted |
| Clonidine Hydrochloride1MG/10ML (0.1MG/ML) · injectable;injection | Clonidine Hydrochloride | Rx |
| Clonidine Hydrochloride5MG/10ML (0.5MG/ML) · injectable;injection | Clonidine Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters